HONG KONG – The Malaysian government is setting a five-year data protection structure for biologics in the country under the terms of the Trans-Pacific Partnership (TPP). That could mean more expensive drugs for the people and better protection for drugmakers.
HONG KONG – Through efforts such as China Made 2025, the Thousand Talents program and its five-year plans, China has been putting considerable work into innovation and has emerged as a prolific patent filer that is closing the R&D gap with the U.S. and EU despite a late start in areas such as biotech.
HONG KONG – The China Securities Regulatory Commission (CSRC) said Friday it plans to lift the four-month ban on IPOs that started during a bout of extreme volatility in the financial markets in Mainland China throughout June and July.
HONG KONG – Through efforts such as China Made 2025, the Thousand Talents program and its five-year plans, China has been putting considerable work into innovation and has emerged as a prolific patent filer that is closing the R&D gap with the U.S. and EU despite a late start in areas such as biotech.
HONG KONG – The CFDA released new regulations to accelerate drug approvals and enhance the integrity of clinical data. At the same time, the regulator is soliciting opinions on a fast-lane approval process for novel drugs.
HONG KONG — One of the biggest Chinese medical device companies is undergoing a $3 billion delisting from the U.S. market as it paves the way to head back to its home market and the possibility of more access to investment.
HONG KONG – The China Securities Regulatory Commission (CSRC) said Friday it plans to lift the four-month ban on IPOs that started during a bout of extreme volatility in the financial markets in Mainland China throughout June and July.
HONG KONG – The CFDA released new regulations to accelerate drug approvals and enhance the integrity of clinical data. At the same time, the regulator is soliciting opinions on a fast-lane approval process for novel drugs.
HONG KONG – In a deal with a South Korean biotech, French pharma major Sanofi SA is collecting more diabetes drugs for its pipeline, aiming to mitigate the impact on its diabetes business, which has seen a 6.6 percent decline in the global market.
